Latest From Zydus Cadila
Takeda appoints new country head for India and aims to improve patient access to innovative medicines in the largely out-of-pocket market.
India permits medicines placed on a restricted list to be exported from SEZs and under advance licenses, but paracetamol exporters hope for more easing as restrictions begin to hurt. Meanwhile, the government asks industry to ensure four months of stock as it balances medicines security with economic interest.
Partnership will combine AbCellera’s screening of antibodies to the virus with Lilly’s development, commercial capabilities. Vir adds Biogen tie-up to its ongoing coronavirus efforts.
Cadila Healthcare has entered the immuno-oncology race by inking a licensing agreement with US-based XOMA for a drug candidate that combines the Indian firm's interleukin-2 with the latter’s novel anti-IL-2 monoclonal antibody
- Generic Drugs
- OTC, Consumer
- Therapeutic Areas
- Parent & Subsidiaries
- Zydus Cadila
- Senior Management
- Pankaj R Patel, Chmn. & Managing Dir.
- Contact Info
Phone: (91) 79 26868100
Zydus Tower, Satellite Cross Roads
Ahmedabad , 380015
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.